## ASO VISUAL ABSTRACT

## ASO Visual Abstract: Feasibility of Preoperative Dose-Painting Intensity-Modulated Radiation Therapy (IMRT) for Borderline Resectable Primary Retroperitoneal Sarcoma


Minsi Zhang, MD, PhD<sup>1</sup>, Aimee Crago, MD, PhD<sup>2</sup>, Sam S. Yoon, MD<sup>2</sup>, Samuel Singer, MD<sup>2</sup>, and Kaled Alektiar, MD<sup>1</sup>

<sup>1</sup>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

While preoperative radiation for resectable retroperitoneal sarcoma is controversial, it may be important for those with borderline resectable disease. This study (https://doi.org/10.1245/s10434-022-12053-7) reports the oncologic and toxicity outcomes of patients with primary

borderline resectable retroperitoneal sarcoma (RPS) treated with preoperative dose-painting intensity-modulated radiation therapy (IMRT) followed by planned resection.

**DISCLOSURE** Dr. Aimee Crago, advisory board—SpringWorks Therapeutics.



© Society of Surgical Oncology 2022

Published Online: 24 August 2022

K. Alektiar, MD

e-mail: alektiak@mskcc.org

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.